Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TYMP | P19971 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4660487 | 0.90 | SLC29A1 (0.44) | CYP1A2TYMPSLC29A1ADORA2AADORA2B | |
| SCHEMBL5977733 | 0.90 | SLC29A1 (0.44) | CYP1A2TYMPSLC29A1ADORA2AADORA2B | |
| SCHEMBL12718330 | 0.84 | TK2 (0.40) | CYP1A2TYMP | |
| SCHEMBL7612678 | 0.84 | TYMP (0.53) | TYMP | |
| SCHEMBL13969908 | 0.83 | TYMP (0.48) | TYMPADORA2AADORA2BSLC5A2 | |
| SCHEMBL7111475 | 0.82 | TYMP (0.48) | TYMP | |
| SCHEMBL12718534 | 0.80 | TYMP (0.53) | TYMPSLC5A2 | |
| SCHEMBL12718548 | 0.80 | TYMP (0.53) | TYMPSLC5A2 | |
| SCHEMBL13970035 | 0.79 | TYMP (0.52) | TYMPSLC29A1SLC5A2 | |
| SCHEMBL13949113 | 0.79 | TYMP (0.52) | TYMPSLC29A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928210-B2 | Nucleoside based proliferation imaging markers | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090016958-A1 | Nucleoside based proliferation imaging markers | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090016958-A1 | Nucleoside based proliferation imaging markers | MKI67, SLC29A1, SLC29A2 | CYP1A2 4804/4885TYMP 5/4885SLC29A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.